Literature DB >> 7085374

Seminoma of the testis: results of treatment and patterns of failure after radiation therapy.

G M Thomas, W D Rider, A J Dembo, B J Cummings, M Gospodarowicz, N V Hawkins, J G Herman, C W Keen.   

Abstract

Four hundred and forty-four patients with the histological diagnosis of pure seminoma were treated at The Princess Margaret Hospital between 1958 and 1976. Using the Walter Reed Hospital staging classification, 338 patients (76.1%) were Stage I, 86 (19.4%) were Stage II, and 20 (4.7%) were Stage III. The 5 year actuarial survival rate (5 yr Sa) for all stages was 87%, and for Stages I, II and III: 94%, 74% and 32% respectively. In Stage II the 5-year Sa was significantly worse when palpable abdominal disease was present (62%, vs 87% when it was absent, p less than .02). Prophylactic mediastinal irradiation was not used for patients with Stage II disease. None of 40 Stage II patients without palpable abdominal disease recurred in the non-irradiated mediastinum. Ten of 46 Stage II patients with palpable abdominal disease recurred in the mediastinum; 7 of the 10 were cured with mediastinal irradiation at the time of relapse. Prophylactic mediastinal irradiation appears unnecessary in Stage II patients. The Stage III category includes a subgroup of patients who were curable with radiation therapy:L 5/6 with supradiaphragmatic nodal disease without palpable abdominal or visceral disease were cured. Exploration of new treatment methods appears indicated for the salvage of patients recurring in sites other than the mediastinum or supraclavicular fossa and for patients presenting with visceral disease.

Entities:  

Mesh:

Year:  1982        PMID: 7085374     DOI: 10.1016/0360-3016(82)90509-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Mortality in patients with testicular cancer.

Authors:  R E Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

2.  Testicular neoplasms: seminoma.

Authors:  E K Reddy; M Burke; S Giri; L Krishnan; L Gemer; R Evans; W K Mebust; J Wiegel
Journal:  J Natl Med Assoc       Date:  1990-09       Impact factor: 1.798

Review 3.  Update in cancer chemotherapy: genitourinary tract cancer, Part 4: Testicular cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-04       Impact factor: 1.798

4.  Curability of third ventricular region tumours. A multidisciplinary approach to evaluate the places of operative, radiation and chemotherapy.

Authors:  E Suc; A Pons; H Roche; M Gigaud; M Carton
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Testicular seminoma: 20-year experience at the Northern Israel Oncology Center (1968-1988).

Authors:  M Stein; M Steiner; B Moshkowitz; D Sapir; I Kessel; A Kuten
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

6.  The treatment of advanced seminoma with chemotherapy and radiotherapy.

Authors:  P M Wilkinson; G Read; B Magee
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

7.  Chemotherapy of metastatic seminoma.

Authors:  J Schuette; N Niederle; M E Scheulen; S Seeber; C G Schmidt
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

8.  Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).

Authors:  M J Peckham; A Horwich; W F Hendry
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

9.  Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.

Authors:  S Sleijfer; P H Willemse; E G de Vries; W T van der Graaf; H Schraffordt Koops; N H Mulder
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

Authors:  S D Fosså; J P Droz; G Stoter; S B Kaye; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.